Search results
Showing 1051 to 1065 of 1237 results for pain
Cabozantinib for previously treated advanced renal cell carcinoma (TA463)
Evidence-based recommendations on cabozantinib (Cabometyx) for previously treated advance renal cell carcinoma in adults.
Berotralstat for preventing recurrent attacks of hereditary angioedema (TA738)
Evidence-based recommendations on berotralstat (Orladeyo) for preventing recurrent attacks of hereditary angioedema in people 12 years and older.
Evidence-based recommendations on blinatumomab (Blincyto) with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive minimal residual disease-negative B-cell precursor acute lymphoblastic leukaemia in adults.
Evidence-based recommendations on pembrolizumab (Keytruda) with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma in adults.
Drug-eluting stents for treating coronary artery disease: late-stage assessment (HTG747)
Late-stage assessment (LSA) guidance on drug-eluting stents for treating coronary artery disease.
View recommendations for HTG747Show all sections
This guideline covers assessing and managing psoriasis in adults, young people and children. It aims to improve long-term disease control and quality of life for people with psoriasis.
This quality standard covers the additional antenatal care for women who are pregnant with twins or triplets that is offered alongside routine antenatal care. It describes high-quality care in priority areas for improvement.
View quality statements for QS46Show all sections
Sections for QS46
- Quality statements
- Quality statement 1: Determining chorionicity and amnionicity
- Quality statement 2: Labelling the fetuses
- Quality statement 3: Composition of the multidisciplinary core team
- Quality statement 4: Care planning
- Quality statement 5: Monitoring for fetal complications
- Quality statement 6: Involving a consultant from a tertiary level fetal medicine centre
- Quality statement 7: Advice and preparation for preterm birth
NICE has developed a medtech innovation briefing (MIB) on The Insides System for managing intestinal failure .
Evidence-based recommendations on brentuximab vedotin (Adcetris) for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma in adults.
Sarilumab for moderate to severe rheumatoid arthritis (TA485)
Evidence-based recommendations on sarilumab (Kevzara) for treating moderate to severe rheumatoid arthritis in adults.
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (HST34)
Evidence-based recommendations on cerliponase alfa (Brineura) for treating neuronal ceroid lipofuscinosis type 2 in children.
NICE has developed a Medtech Innovation Briefing (MIB) on the Oncentra Prostate v4.x ultrasound-guided real-time HDR brachytherapy in men with localised
NICE has developed a medtech innovation briefing (MIB) on the Secca System for faecal incontinence
Otovent nasal balloon for otitis media with effusion (MIB59)
NICE has developed a medtech innovation briefing (MIB) on the Otovent nasal balloon for otitis media with effusion
NICE has developed a Medtech Innovation Briefing (MIB) on the SpyGlass direct visualisation system for diagnostic and therapeutic procedures during endoscopy of